check quantity

Epic Polar LC Columns - 150 mm, 4.6 mm I.D., 5 μm

Epic Polar is a high density C18 packing specifically engineered for the retention of polar analytes and allows full interaction with the bonded hydrocarbon phase, even in 100% aqueous mobile phases. Under these highly aqueous conditions, our novel proprietary bonding chemistry allows the bonded chains to remain fully extended in the mobile phase. Epic Polar can retain highly water-soluble compounds such as small organic acids, water-soluble vitamins, purines and pyrimidines, cathecholamines and other polar compounds.

Part Number
Inner Diameter
Particle Size
List Price
Your Price
4.6 mm
3.0 µm
646.00 USD
4.6 mm
5.0 µm
649.00 USD
Buy Now

Please enter valid quantity

Please log in to add favorites.



The Epic line our latest range of LC columns, based on high density monomerically bonded phases produced through a proprietary bonding process. Epic HPLC and UHPLC columns are compatible with a wide range of organic modifiers and buffers and stable over a wide pH range. All Epic products use an ultra-high purity metal free silica and undergo strict quality control testing. For flexibility, we offer a wide range of column sizes as well being fully scalable from analytical to preparative dimensions.

Features and Benefits:

  • Ultra-high purity silica for improved peak shape, especially for basic compounds
  • Extensive range of stationary phase chemistries with innovative bonding chemistry to enhance method development
  • High density bonding produces columns with better pH stability, increased sample loading and better lot-to-lot reproducibility
  • Extended pH stability across commonly used mobile phase buffers
  • Microbore to preparative dimensions available to allow flexibility and full scalability


Inner Diameter 4.6 mm
Length 150.0 mm
Particle Size 5.0 µm
Phase Polar
Resources, Events & More
  • All

Application Brief

HPLC Analysis of Levetiracetam Using Epic C18, Epic C18-SD, and Epic Polar Columns in Accordance with the USP

Levetiracetam was approved for medical use in the United States in 1999 and is available as a generic medication.1 Levetiracetam is a novel anticonvulsant agent used as an adjunct medication to manage partial onset, myoclonic, and generalized tonic-clonic seizures in patients with epilepsy. It is ...

PDF 361 KB